Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

IN VITRO DIAGNOSTIC TESTING BY PATIENTS AT HOME WILL GROW 27% per year between now and 1990, Boston Biomedical Consultants President Henry Weinert predicted Aug. 1 at a briefing on the in vitro diagnostic market held at the 36th annual meeting of the American Assn. for Clinical Chemistry in Washington, D.C. In 1983, at-home testing accounted for about 2%, or $56 mil., of a total $2.6 bil. U.S. market for laboratory assays, newly distributed in vitro diagnostics, and DNA probe products, according to Weinert. By 1990, at-home testing will increase to about $294 mil., Weinert noted. Self-testing will be the fastest growing site for in vitro diagnostics, Weinert said, in line with shifting test locations due to cost-containment concerns. Commercial labs will show the slowest market growth, predicted Weinert, at about 6% a year. Hospital lab locations will increase diagnostic testing by about 11% a year between now and 1990; clinics and health maintenance organizations will grow about 19% a year; and the physician's office location will increase 16%, Weinert said. Overall, basic demand for routine in vitro diagnostic tests will be stable at an annual growth rate of 10%, according to the health care consulting firm. That growth rate is driven by an increasing physician, or requestor, population, Weinert explained. In 1982, there were a total of 440,000 physicians in practice in the U.S., he said. By 1990, that number will climb 2.4% to 530,000. In 1983, the U.S. testing volume was 6.7 bil. tests, Boston Biomedical's Ruth Emyanitoff, PhD, stated at the briefing. Hospitals performed 4 bil. of those tests, commercial labs accounted for 2 bil., outpatient facilities and physician's office each performed 280 mil., and patients at home performed about 140 mil. tests, she said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts